Key result
Brain-selective ACE2 overexpression reduces renal sympathetic nerve activity by ~22 percentage points in heart failure.
Why the study?
Does brain-selective overexpression of ACE2 reduce sympathetic outflow and enhance baroreflex function in a mouse model of chronic heart failure?
Does brain-selective overexpression of ACE2 reduce sympathetic outflow and enhance baroreflex function in a mouse model of chronic heart failure?
Brain-selective ACE2 overexpression attenuates sympathetic outflow and enhances baroreflex function in a mouse model of chronic heart failure, suggesting a protective central mechanism involving angiotensin (1-7) mas signaling.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for central ACE2 in HF sympathetic control; leaves open translation to human therapy.
Angiotensin-converting enzyme 2 (ACE2) has been suggested to be involved in the central regulation of autonomic function. During chronic heart failure (CHF), elevated central angiotensin II signaling contributes to the sustained increase of sympathetic outflow. This is accompanied by a downregulation of ACE2 in the brain. We hypothesized that central overexpression of ACE2 decreases sympathetic outflow and enhances baroreflex function in CHF. Transgenic mice overexpressing human ACE2 selectively in the brain (SYN-hACE2 [SA]) and wild-type littermates (WT) were used. CHF was induced by permanent coronary artery ligation. Four weeks after coronary artery ligation, both WT and SA mice exhibited a significant decrease in left ventricular ejection fraction (<40%). A slight decrease in mean arterial pressure was found only in SA mice. Compared with WT mice with CHF, brain-selective ACE2 overexpression attenuated left ventricular end-diastolic pressure; decreased urinary norepinephrine excretion; baseline renal sympathetic nerve activity (WT CHF: 71.6±7.6% max versus SA CHF: 49.3±6.1% max); and enhanced baroreflex sensitivity (maximum slope: WT sham: 1.61±0.16%/mm Hg versus SA CHF: 1.51±0.17%/mm Hg). Chronic subcutaneous blockade of mas receptor increased renal sympathetic nerve activity in SA mice with CHF (A779: 67.3±5.8% versus vehicle: 46.4±3.6% of max). An upregulation in angiotensin II type 1 receptor expression was detected in medullary nuclei in WT CHF mice, which was significantly attenuated in SA mice with CHF. These data suggest that central ACE2 overexpression exerts a potential protective effect in CHF through attenuating sympathetic outflow. The mechanism for this effect involves angiotensin (1-7) mas signaling, as well as a decrease in angiotensin II type 1 receptor signaling in the medulla.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2011) studied Chronic Heart Failure (Preclinical Mouse Model). Brain-selective overexpression of human ACE2 (SYN-hACE2 transgene) vs. Wild-type non-transgenic littermates with CHF was evaluated on Baseline renal sympathetic nerve activity (RSNA, % of maximum) (p=<0.05). Brain-selective ACE2 overexpression reduced baseline renal sympathetic nerve activity (49.3% vs 71.6% max, p<0.05) and improved baroreflex sensitivity in mice with chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: